Evidence map›Paper›PMID 28912210›Full record

Trial reportJournal of the American Heart Association2017

Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.

Patricia Oliveira Guimarães, Christopher B Granger, Amanda Stebbins, Karen Chiswell, Claes Held, Judith S Hochman, Susan Krug-Gourley, Eva Lonn, Renato D Lopes, Ralph A H Stewart and 5 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00799903 (LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00799903 phase3completednot on this map

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

TypeinterventionalSponsorGlaxoSmithKlineRan2008 to 2013Enrolled15,828ConditionsAtherosclerosisArmsDarapladib, Placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Reappraising Ischemic Heart Disease in Women.Reviews in cardiovascular medicine · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Patricia Oliveira GuimarãesDuke Clinical Research Institute, Durham, NC.
Christopher B GrangerDuke Clinical Research Institute, Durham, NC christopher.granger@duke.edu.
Amanda StebbinsDuke Clinical Research Institute, Durham, NC.
Karen ChiswellDuke Clinical Research Institute, Durham, NC.
Claes HeldDepartment of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Judith S HochmanDepartment of Medicine, NYU Langone Medical Center, New York, NY.
Susan Krug-GourleyMetabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, Collegeville, PA.
Eva LonnDepartment of Medicine and Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
Renato D LopesDuke Clinical Research Institute, Durham, NC.
Ralph A H StewartGreen Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand.
Dragos VinereanuUniversity of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Lars WallentinDepartment of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Harvey D WhiteGreen Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand.
Emil HagströmDepartment of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Nicolas DanchinHôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, INSERM U-970 and Université Paris Descartes, Paris, France.

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
NCATS NIH HHS UL1 TR001445
6 · The paper itself

Abstract

backgroundGreater understanding of differences between men and women with coronary heart disease is needed. METHODS AND

resultsIn this post hoc analysis of the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial, we described psychosocial factors, treatments, and outcomes of men versus women with stable coronary heart disease and explored the association of sex with psychosocial characteristics and cardiovascular risk. Cox proportional hazards models were used to assess the relationship between sex and outcomes. Interactions among sex, psychosocial factors, and the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke were tested. Of 15 828 patients, 2967 (19%) were women. Among women, 21.2% felt often or always stressed at home (versus 9.8% of men), and 19.2% felt often or always sad or depressed (versus 10.1% of men; all

conclusionsFemale sex was independently associated with better long-term clinical outcomes, although this was modified by frequency of depressive symptoms. This suggests that emotional state may be an important target for improving outcomes in patients with coronary heart disease, specifically in women. CLINICAL

trial registrationSTABILITY ClinicalTrials.gov number (NCT00799903).

Indexed as

Risk AssessmentAgedBenzaldehydesBiphenyl CompoundsCoronary Artery DiseaseDiethylaminesDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansIncidenceMaleMiddle AgedOximesPlaque, AtheroscleroticPsychometricsBenzaldehydesBiphenyl CompoundsdarapladibDiethylaminesOximesPyrimidinonesSulfidescardiovascular diseasedepressionpsychosocial factorsrisksex

Identifiers

PMID28912210
PMCPMC5634306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.